Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Big Pharma, it’s time to talk: Investors demand transparency on patent thickets

By Brian Buntz | March 29, 2023

[PIRO4D/Pixabay]

Pharmaceutical companies are running into pushback for their “patent thicket” tactics, designed to maintain exclusive rights and delay cheaper generics. The Financial Times reported that an ethical investor coalition is pushing for greater transparency and urging major drug makers to disclose their patent strategies.

Unraveling the patent thicket mystery

Patent thickets are a common intellectual property tactic in pharma. Companies file numerous patents beyond the primary one for a specific compound. Critics say this cunning approach stalls the introduction of generics even after the 20-year exclusivity of primary patents expires. Consequently, drug prices remain high, and affordable medications remain out of reach for many.

Drugs like Humira (adalimumab) and Keytruda (pembrolizumab), for example, have experienced extended periods without biosimilar or generic competition, leading to steep prices and limited patient access. Earlier this month, Sandoz, a Novartis (NYSE:SIX) subsidiary, received FDA approval for its Humira biosimilar Hyrimoz (adalimumab-adaz).

Ethical investors demand answers

A powerful ethical investor coalition, featuring Mercy Investment Services and Trinity Health, is questioning major pharmaceutical companies like Johnson & Johnson (NYSE:JNJ), Merck & Co. (NYSE:MRK), Pfizer (NYSE:PFE), Eli Lilly (NYSE:LLY), Gilead Sciences, (Nasdaq:GILD), Amgen (Nasdaq:AMGN), Regeneron (Nasdaq:REGN), Bristol Myers Squibb (NYSE:BMY) and AbbVie (NYSE:ABBV). They want reports on single-drug patent application processes and answers about whether these strategies intentionally prolong exclusivity for top-selling drugs and how they impact patient access.

Big Pharma resists patent thicket scrutiny

Eight of the nine targeted companies are fighting shareholder proposals at the Securities and Exchange Commission (SEC). It’s a common tactic among corporations. Bristol Myers Squibb, however, is taking a different approach, engaging in talks with the investors, as reported in the Financial Times.

In June, six U.S. senators from both parties urged the U.S. Patent and Trademark Office (USPTO) to act against patent thickets that allegedly suppress competition and inflate drug prices. They criticized granting multiple patents for minor variations on a single invention and called on the USPTO to issue proposed rules or request public comment by September, according to Reuters.

Public debate and healthcare costs: A heated exchange

Patent thickets have ignited a public debate about their role in perpetuating high drug prices and limiting access to affordable generics. Lydia Kuykendal, director of shareholder advocacy at Mercy Investment Services, argues that the lack of competition resulting from patent thickets lets manufacturers inflate prices, contributing to the U.S.’ costly healthcare system.

This ongoing debate highlights the need to balance intellectual property rights with affordable patient access to medications. Ethical investors are championing change, advocating for more transparency and accountability in the pharmaceutical industry. They demand fair drug pricing and broader patient access to essential medications and show no signs of backing down.


Filed Under: Drug Discovery, Drug Discovery and Development
Tagged With: Big Pharma, drug pricing, ethical investors, generic drugs, patent strategies, patient access, Transparency
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE